CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and overcomes PARPi resistance in PDX models of HGSOC.

Guardado en:

Detalles Bibliográficos
Autores principales:	Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, Shunfei Yan, Jessica E. Ahern, Anna S. Trigos, Natalie Brajanovski, Jinbae Son, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J. Deans, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M. J. J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e147f3013f3440d1be5ac0b31368773d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e147f3013f3440d1be5ac0b31368773d
record_format	dspace
spelling	oai:doaj.org-article:e147f3013f3440d1be5ac0b31368773d2021-12-02T15:00:12ZCX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer10.1038/s41467-020-16393-42041-1723https://doaj.org/article/e147f3013f3440d1be5ac0b31368773d2020-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-16393-4https://doaj.org/toc/2041-1723Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and overcomes PARPi resistance in PDX models of HGSOC.Elaine SanijKatherine M. HannanJiachen XuanShunfei YanJessica E. AhernAnna S. TrigosNatalie BrajanovskiJinbae SonKeefe T. ChanOlga KondrashovaElizabeth LieschkeMatthew J. WakefieldDaniel FrankSarah EllisCarleen CullinaneJian KangGretchen PoortingaPurba NagAndrew J. DeansKum Kum KhannaLinda MileshkinGrant A. McArthurJohn SoongEls M. J. J. BernsRoss D. HannanClare L. ScottKaren E. SheppardRichard B. PearsonNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Elaine Sanij Katherine M. Hannan Jiachen Xuan Shunfei Yan Jessica E. Ahern Anna S. Trigos Natalie Brajanovski Jinbae Son Keefe T. Chan Olga Kondrashova Elizabeth Lieschke Matthew J. Wakefield Daniel Frank Sarah Ellis Carleen Cullinane Jian Kang Gretchen Poortinga Purba Nag Andrew J. Deans Kum Kum Khanna Linda Mileshkin Grant A. McArthur John Soong Els M. J. J. Berns Ross D. Hannan Clare L. Scott Karen E. Sheppard Richard B. Pearson CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
description	Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and overcomes PARPi resistance in PDX models of HGSOC.
format	article
author	Elaine Sanij Katherine M. Hannan Jiachen Xuan Shunfei Yan Jessica E. Ahern Anna S. Trigos Natalie Brajanovski Jinbae Son Keefe T. Chan Olga Kondrashova Elizabeth Lieschke Matthew J. Wakefield Daniel Frank Sarah Ellis Carleen Cullinane Jian Kang Gretchen Poortinga Purba Nag Andrew J. Deans Kum Kum Khanna Linda Mileshkin Grant A. McArthur John Soong Els M. J. J. Berns Ross D. Hannan Clare L. Scott Karen E. Sheppard Richard B. Pearson
author_facet	Elaine Sanij Katherine M. Hannan Jiachen Xuan Shunfei Yan Jessica E. Ahern Anna S. Trigos Natalie Brajanovski Jinbae Son Keefe T. Chan Olga Kondrashova Elizabeth Lieschke Matthew J. Wakefield Daniel Frank Sarah Ellis Carleen Cullinane Jian Kang Gretchen Poortinga Purba Nag Andrew J. Deans Kum Kum Khanna Linda Mileshkin Grant A. McArthur John Soong Els M. J. J. Berns Ross D. Hannan Clare L. Scott Karen E. Sheppard Richard B. Pearson
author_sort	Elaine Sanij
title	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
title_short	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
title_full	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
title_fullStr	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
title_full_unstemmed	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
title_sort	cx-5461 activates the dna damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/e147f3013f3440d1be5ac0b31368773d
work_keys_str_mv	AT elainesanij cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT katherinemhannan cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT jiachenxuan cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT shunfeiyan cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT jessicaeahern cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT annastrigos cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT nataliebrajanovski cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT jinbaeson cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT keefetchan cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT olgakondrashova cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT elizabethlieschke cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT matthewjwakefield cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT danielfrank cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT sarahellis cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT carleencullinane cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT jiankang cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT gretchenpoortinga cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT purbanag cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT andrewjdeans cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT kumkumkhanna cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT lindamileshkin cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT grantamcarthur cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT johnsoong cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT elsmjjberns cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT rossdhannan cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT clarelscott cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT karenesheppard cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer AT richardbpearson cx5461activatesthednadamageresponseanddemonstratestherapeuticefficacyinhighgradeserousovariancancer
_version_	1718389234342035456

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Ejemplares similares